Literature DB >> 24820452

Quality of life in psoriasis patients.

Matthias Augustin1, Marc Alexander Radtke.   

Abstract

Patient-reported outcomes are major components of decision making in clinical research, reimbursement, health policy and health care for psoriasis. The most important construct in patient-reported outcomes is health-related quality of life (HRQoL) which encompasses the individual's well-being with respect to health. HRQoL cannot directly be measured but is assessed in single dimensions, especially physical, emotional, social and functional aspects. For this, disease- and condition-specific instruments are used. Psoriasis is a chronic inflammatory disease affecting the skin as well as other tissues and organ systems. Patients suffer from a large scale of impairments, for example, physical symptoms, stigmatization and embarrassment, psychological strain and disabilities in profession. Improvement of HRQoL is a major objective of disease management. Current knowledge on determinants of HRQoL and the treatments available increase QoL in clinical care.

Entities:  

Keywords:  cumulative life course impairment; disease burden; psoriasis; quality of life; stigmatization

Mesh:

Year:  2014        PMID: 24820452     DOI: 10.1586/14737167.2014.914437

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  19 in total

1.  How important is subjective well-being for patients? A qualitative interview study of people with psoriasis.

Authors:  Antonia-Luise Newi; Athanasios Tsianakas; Sophia von Martial; Rachel Sommer; Christine Blome
Journal:  Qual Life Res       Date:  2022-08-10       Impact factor: 3.440

Review 2.  Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.

Authors:  Agnieszka Wasilewska; Marta Winiarska; Małgorzata Olszewska; Lidia Rudnicka
Journal:  Postepy Dermatol Alergol       Date:  2016-08-16       Impact factor: 1.837

Review 3.  Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.

Authors:  Michael Roman; Melvin W Chiu
Journal:  Drug Des Devel Ther       Date:  2017-07-07       Impact factor: 4.162

4.  First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

Authors:  Sophie Glatt; Eric Helmer; Birgit Haier; Foteini Strimenopoulou; Graham Price; Pavan Vajjah; Olivier A Harari; John Lambert; Stevan Shaw
Journal:  Br J Clin Pharmacol       Date:  2017-01-10       Impact factor: 4.335

5.  Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.

Authors:  M M Hutmacher; K Papp; S Krishnaswami; K Ito; H Tan; R Wolk; H Valdez; C Mebus; S T Rottinghaus; P Gupta
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-03-20

6.  Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data.

Authors:  April W Armstrong; J Will Koning; Simon Rowse; Huaming Tan; Carla Mamolo; Mandeep Kaur
Journal:  Dermatol Ther (Heidelb)       Date:  2016-11-30

Review 7.  Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.

Authors:  Stephen Chu-Sung Hu; Cheng-Che E Lan
Journal:  Int J Mol Sci       Date:  2017-10-21       Impact factor: 5.923

Review 8.  Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review.

Authors:  Sandra Ly; Jean Michel Amici
Journal:  Drugs Context       Date:  2018-08-20

9.  Management of a Chronic Skin Disease in Primary Care: An Analysis of Early-Career General Practitioners' Consultations Involving Psoriasis.

Authors:  Sameerah Nawaz; Amanda Tapley; Andrew R Davey; Mieke L van Driel; Alison Fielding; Elizabeth G Holliday; Jean Ball; Irena Patsan; Alyse Berrigan; Simon Morgan; Neil A Spike; Kristen FitzGerald; Parker Magin
Journal:  Dermatol Pract Concept       Date:  2021-05-20

10.  The Lived Experience of Psoriasis Patients from Social Stigma and Rejection: A Qualitative Study.

Authors:  Alireza Ghorbanibirgani; Masoud Fallahi-Khoshknab; Kourosh Zarea; Heidarali Abedi
Journal:  Iran Red Crescent Med J       Date:  2016-05-21       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.